Australia's Imugene rises on approval to start trial for cancer treatment

Hanall Biopharma

10/05/2022 05:16

** Shares of cancer-focused biopharma co Imugene  IMU.AX 
climb as much as 9.4% to A$0.175
    ** Co receives https://www.asx.com.au/asxpdf/20220510/pdf/458vgwk8p1rdy5.pdf
 ethics approval to start a Phase 2 clinical trial of its
immunotherapy candidate HER-Vaxx in Australia
    ** "The start of our Australian study is a significant
milestone for Imugene and clinicians treating those faced with
the challenge of HER-2+ gastric cancer," IMU says
    ** Ethics approval confirms that co has completed the
necessary pre-clinical safety and efficacy testing of HER-Vaxx
require to start its nextHERIZON clinical trial in Australia
    ** Stock on track for best day since May 5
    ** As of last close, IMU down ~60% this year
    


 (Reporting by Upasana Singh in Bengaluru)
 ((Upasana.Singh@thomsonreuters.com))